8.8 C
New York
Wednesday, March 22, 2023

Taking On Challenges And Growing? – Seres Therapeutics Inc. (MCRB)

After Hours

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. After-hours trades for Seres Therapeutics Inc. (MCRB) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.05, or 0.93%, to $5.45. The Seres Therapeutics Inc. has recorded 3,006 volume in the after hours trading session. Earlier, Yahoo Finance discussed this stock as it revealed Seres Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".


Stocks Info

Seres Therapeutics Inc. is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $5.40 and fluctuated between $5.43 as its day high and $4.88 as its day low. The current market capitalization of Seres Therapeutics Inc. is $675.32M. A total of 1.73 million shares were traded on the day, compared to an average of 748.30K shares.

Insider trades are also considered as indicators of how a stock will perform in the future, in addition to stock predictions. During the recent three months, MCRB has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 15 BUYs and 1 SELLs from insiders. Insiders purchased 9,281,933 shares during that period but sold 5,012.

In the most recent transaction, Ege David S. sold 5,012 shares of MCRB for 7.93 per share on Oct 31. After the transaction, the insider now owns 46,734 company shares. In a previous transaction on Jul 05, Nutritional Health LTP Fund Ge bought 8,738,243 shares at 3.15 per share. MCRB shares that 10% Owner owns now total 5,875,711.

Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. According to analysts who have offered 12-month price targets for MCRB in the last 3 months, the mean price target is $12.50 with high estimates of $25.00 and low estimates of $4.00. In terms of 52-week highs and lows, MCRB has a high of $9.49 and a low of $2.50.

As of this writing, MCRB has an earnings estimate of -$0.46 per share for the current quarter. EPS was calculated based on a consensus of 8 estimates, with a high estimate of -$0.3 per share and a lower estimate of -$0.55. The company reported an EPS of -$0.7 in the last quarter, which was -16.70% lower than expectations of -$0.6.

Balance Sheet Annually/Quarterly

As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information.

Analysts Opinion

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 7 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for MCRB is Overweight with a score of 5.00. A total of 6 analysts rated the stock as Buy while 0 rated it as Overweight while 0 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 1 thought it should be Sold.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles